PHGDH-mediated Endothelial Metabolism Drives Glioblastoma Resistance to Chimeric Antigen Receptor T Cell Immunotherapy.

Duo Zhang,Albert M. Li,Guanghui Hu,Menggui Huang,Fan Yang,Lin Zhang,Kathryn E. Wellen,Xiaowei Xu,Crystal S. Conn,Wei Zou,Mark Kahn,Seth D. Rhoades,Aalim M. Weljie,Serge Y. Fuchs,Nduka Amankulor,Daniel Yoshor,Jiangbin Ye,Constantinos Koumenis,Yanqing Gong,Yi Fan
DOI: https://doi.org/10.1016/j.cmet.2023.01.010
IF: 29
2023-01-01
Cell Metabolism
Abstract:The efficacy of immunotherapy is limited by the paucity of T cells delivered and infiltrated into the tumors through aberrant tumor vasculature. Here, we report that phosphoglycerate dehydrogenase (PHGDH)-medi-ated endothelial cell (EC) metabolism fuels the formation of a hypoxic and immune-hostile vascular microen-vironment, driving glioblastoma (GBM) resistance to chimeric antigen receptor (CAR)-T cell immunotherapy. Our metabolome and transcriptome analyses of human and mouse GBM tumors identify that PHGDH expres-sion and serine metabolism are preferentially altered in tumor ECs. Tumor microenvironmental cues induce ATF4-mediated PHGDH expression in ECs, triggering a redox-dependent mechanism that regulates endo-thelial glycolysis and leads to EC overgrowth. Genetic PHGDH ablation in ECs prunes over-sprouting vascu-lature, abrogates intratumoral hypoxia, and improves T cell infiltration into the tumors. PHGDH inhibition ac-tivates anti-tumor T cell immunity and sensitizes GBM to CAR T therapy. Thus, reprogramming endothelial metabolism by targeting PHGDH may offer a unique opportunity to improve T cell-based immunotherapy.
What problem does this paper attempt to address?